Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Pluri Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology...
Pluri (NASDAQ:PLUR) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.73) by 36...
-SEC Filing
Alliance Global Partners analyst Matthew Venezia initiates coverage on Pluri (NASDAQ:PLUR) with a Buy rating and announces P...
Pluri (NASDAQ:PLUR) reported quarterly losses of $(0.94) per share. This is a 6.93 percent increase over losses of $(1.01) per ...
Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based...
